Novartis Stock Down On Weak Q4 Results; Sees Growth In FY23

Published on 1 Feb 2023 on RTT News

Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after...

Read the rest of the article

Start tracking your investments with Statfolio

Novartis NVS presented encouraging results from a pre-specified interim analysis of the phase III...

Zacks via Yahoo Finance 16 Apr 2024

There's a common problem with passive income: Generating it isn't as passive as investors expect....

Motley Fool via Yahoo Finance 14 Apr 2024

Novartis NVS entered into an exclusive strategic license agreement with a clinical-stage biotechn...

Zacks via Yahoo Finance 12 Apr 2024

On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences I...

Benzinga 11 Apr 2024

Novartis NVS is set to reduce its workforce by 680, per a report by Reuters. It will do so in its...

Zacks via Yahoo Finance 11 Apr 2024

Alpine Immune’s lead candidate is being evaluated as a potential treatment for IgA Nephropathy, o...

Market Watch 11 Apr 2024

Novartis has commenced its tender offer to acquire MorphoSys for €2.7B, offering a premium of 142...

Seeking Alpha 11 Apr 2024

The offer is set at €68.00 per share, totaling an equity value of €2.7 billion. This price reflec...

Investing.com 11 Apr 2024

The offer price corresponds to a premium of 94% and 142% on the volume-weighted...

Investing.com 11 Apr 2024

Thursday, Novartis AG NVS shares are trading higher after the company confirmed plans to file for...

Benzinga 4 Apr 2024